Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEVIN D CANNON

Allopathic & Osteopathic Physicians Hospitalist

NPI
1700897022
CMS profile
122867
Location
WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$58.19

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $32.27 1
Food and Beverage $25.92 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $32.27 1
Boehringer Ingelheim Pharmaceuticals, Inc. $25.92 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEVIN D CANNON

NPI 1700897022 · CMS profile ID 122867

Allopathic & Osteopathic Physicians / Hospitalist

WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $58.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $25.9208/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887506015 CMS
Novo Nordisk Inc $32.2706/08/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898661569 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,301.48 16
PY2021 $20.00 1
PY2022 $58.19 2
PY2023 $1,400.30 14
PY2025 $116.03 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,200.00 1
PY2025 Principal investigator $6,407,903.58 738
PY2024 Recipient $12,299.41 13
PY2024 Principal investigator $7,058,469.69 390
PY2023 Recipient $3,980.00 2
PY2023 Principal investigator $7,125,617.33 899
PY2022 Recipient $9,082.00 12
PY2022 Principal investigator $6,929,547.49 979
PY2021 Recipient $14,312.20 61
PY2021 Principal investigator $9,361,495.59 2,459
PY2020 Recipient $233.41 1
PY2020 Principal investigator $5,812,787.31 750
PY2019 Principal investigator $4,820,055.08 826

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

901 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $160.65 12/30/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046301723
Principal investigator 1 Novo Nordisk AS $23.06 12/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007847243
Principal investigator 1 PFIZER INC. $6,777.40 12/27/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046122999
Principal investigator 1 Novo Nordisk AS $23.06 12/26/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007847237
Principal investigator 1 PFIZER INC. $10,900.00 12/26/2023 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1045949271
Principal investigator 1 PFIZER INC. $4,437.69 12/22/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046067141
Principal investigator 1 PFIZER INC. $350.00 12/22/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046143699
Principal investigator 1 PFIZER INC. $252.00 12/21/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1045875423
Principal investigator 1 PFIZER INC. $3,406.94 12/21/2023 Non-covered Recipient Entity
Accellacare US Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046078437
Principal investigator 1 PFIZER INC. $125,015.42 12/21/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046262675
Principal investigator 1 BioNTech SE $3,601.00 12/19/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319267
Principal investigator 1 Novo Nordisk AS $15,141.00 12/18/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007127571
Principal investigator 1 Novo Nordisk AS $3,549.75 12/18/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007212807
Principal investigator 1 Novo Nordisk AS $35,873.14 12/18/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007847229
Principal investigator 1 Novo Nordisk AS $95.04 12/14/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007127587
Principal investigator 1 Novo Nordisk AS $95.04 12/14/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007127605
Principal investigator 1 Novo Nordisk AS $95.04 12/14/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543725
Principal investigator 1 Novo Nordisk AS $95.04 12/14/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543741
Principal investigator 1 Novo Nordisk AS $95.04 12/14/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543759
Principal investigator 1 PFIZER INC. $645.70 12/14/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046143715
Principal investigator 1 PFIZER INC. $183,254.76 12/14/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046260635
Principal investigator 1 PFIZER INC. $41.36 12/14/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046274123
Principal investigator 1 BioNTech SE $3,773.00 12/12/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319263
Principal investigator 1 PFIZER INC. $3,013.85 12/12/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046175119
Principal investigator 1 Janssen Research & Development, LLC $102,144.00 12/11/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older No dispute reported 06/30/2026 986150851
Principal investigator 1 PFIZER INC. $550.23 12/10/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046167217
Principal investigator 1 PFIZER INC. $831.00 12/09/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1045922295
Principal investigator 1 PFIZER INC. $3,297.30 12/09/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1045991693
Principal investigator 1 Bavarian Nordic A/S $371.00 12/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704413
Principal investigator 1 Bavarian Nordic A/S $8,366.00 12/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704871
Principal investigator 1 BioNTech SE $2,079.00 12/08/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319259
Principal investigator 1 BioNTech SE $96.00 12/08/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319313
Principal investigator 1 BioNTech SE $900.00 12/08/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319323
Principal investigator 1 GlaxoSmithKline, LLC. $400.00 12/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127783438
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 12/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127786703
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 12/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127792166
Principal investigator 1 PFIZER INC. $403.92 12/08/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046011779
Principal investigator 1 PFIZER INC. $61,727.24 12/07/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1045875409
Principal investigator 1 PFIZER INC. $3,993.41 12/07/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045930851
Principal investigator 1 GlaxoSmithKline, LLC. $8,000.00 12/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 1/2, RANDOMIZED, DOSE-FINDING/DOSE-CONFIRMATION STUDY TO EVALU No dispute reported 06/30/2026 1127783442
Principal investigator 1 GlaxoSmithKline, LLC. $400.00 12/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127783444
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 12/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127783450
Principal investigator 1 GlaxoSmithKline, LLC. $1,600.00 12/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 1/2, RANDOMIZED, DOSE-FINDING/DOSE-CONFIRMATION STUDY TO EVALU No dispute reported 06/30/2026 1127785361
Principal investigator 1 GlaxoSmithKline, LLC. $800.00 12/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127786699
Principal investigator 1 GlaxoSmithKline, LLC. $7,500.00 12/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
AN OPEN-LABEL MULTI-CENTRE ENABLING STUDY TO EVALUATE INFLUENZA LIKE I No dispute reported 06/30/2026 1127786707
Principal investigator 1 GlaxoSmithKline, LLC. $2,250.00 12/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127786711
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 12/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127792174
Principal investigator 1 PFIZER INC. $16,648.25 12/06/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046303195
Principal investigator 1 Novo Nordisk AS $25,000.71 11/29/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1006819609
Principal investigator 1 Bavarian Nordic A/S $742.00 11/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704419
Principal investigator 1 BioNTech SE $3,504.00 11/28/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319273
Principal investigator 1 Novo Nordisk AS $1,985.80 11/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007212795
Principal investigator 1 PFIZER INC. $3,433.31 11/25/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046014235
Principal investigator 1 ModernaTX, Inc. $375.00 11/23/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042060563
Principal investigator 1 ModernaTX, Inc. $1,650.00 11/23/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300057
Principal investigator 1 Novo Nordisk AS $22,126.26 11/22/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007127557
Principal investigator 1 Novo Nordisk AS $1,284.66 11/22/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1009259909
Principal investigator 1 BioNTech SE $8,948.00 11/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319269
Principal investigator 1 BioNTech SE $1,001.00 11/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319325
Principal investigator 1 BioNTech SE $3,000.00 11/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319327
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 11/17/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127786715
Principal investigator 1 PFIZER INC. $3,386.90 11/15/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046044679
Principal investigator 1 PFIZER INC. $345.60 11/14/2023 Non-covered Recipient Entity
Accellacare Wilmington
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046067155
Principal investigator 1 PFIZER INC. $1,078.00 11/14/2023 Non-covered Recipient Entity
Accellacare Wilmington
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046069225
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,500.00 11/13/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095577
Principal investigator 1 PFIZER INC. $362.37 11/11/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046265483
Principal investigator 1 ModernaTX, Inc. $1,340.00 11/09/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042060555
Principal investigator 1 PFIZER INC. $2,461.00 11/09/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046181221
Principal investigator 1 PFIZER INC. $1,600.00 11/09/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046267914
Principal investigator 1 GlaxoSmithKline, LLC. $250.00 11/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127783440
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 11/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127786701
Principal investigator 1 BioNTech SE $5,697.00 11/07/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319257
Principal investigator 1 Bavarian Nordic A/S $12,251.00 11/02/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704437
Principal investigator 1 BioNTech SE $7,748.00 11/02/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319249
Principal investigator 1 PFIZER INC. $11,355.00 10/31/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046119185
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299993
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299995
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299997
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299999
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300001
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300003
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300005
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300007
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300009
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300011
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300013
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300015
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300017
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300019
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300021
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300023
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300025
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300027
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300029
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300031
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300033
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300035
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300037
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300039
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300041
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300043
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300045
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300047
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300049
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300051
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300053
Principal investigator 1 ModernaTX, Inc. $473.24 10/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042300055
Principal investigator 1 GlaxoSmithKline, LLC. $6,500.34 10/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT No dispute reported 06/30/2026 1127792170
Principal investigator 1 PFIZER INC. $3,600.00 10/27/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY WITH LOTIGLIPRON PF07081532 TO ASSESS CARDIOVASCULAR AND OTHER LONGTERM OUTCOMES IN ADULTS WITH TYPE 2 DIABETES MELLITUS No dispute reported 06/30/2026 1046027709
Principal investigator 1 BioNTech SE $1,001.00 10/25/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060312911
Principal investigator 1 BioNTech SE $7,083.00 10/25/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319271
Principal investigator 1 Novo Nordisk AS $865.80 10/25/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1009259893
Principal investigator 1 PFIZER INC. $28,019.20 10/25/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1045876231
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,391.32 10/24/2023 Non-covered Recipient Entity
Pmg Research Of Wilmington
phase III efficacy for obesity with T2DM No dispute reported 06/30/2026 1022137285
Principal investigator 1 Novo Nordisk AS $23.06 10/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007847223
Principal investigator 1 Novo Nordisk AS $13,127.38 10/23/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007127539
Principal investigator 1 Novo Nordisk AS $3,117.80 10/23/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007212781
Principal investigator 1 PFIZER INC. $362.37 10/20/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046133539
Principal investigator 1 BioNTech SE $144.00 10/19/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319315
Principal investigator 1 PFIZER INC. $1,200.12 10/18/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1045999983
Principal investigator 1 PFIZER INC. $171,520.03 10/18/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046076893
Principal investigator 1 BioNTech SE $1,386.00 10/17/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319265
Principal investigator 1 Novo Nordisk AS $23.06 10/16/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007847211
Principal investigator 1 Novo Nordisk AS $23.06 10/16/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007847217
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,721.32 10/13/2023 Non-covered Recipient Entity
Pmg Research Of Wilmington
Phase III efficacy for obesity without T2DM No dispute reported 06/30/2026 1022137279
Principal investigator 1 PFIZER INC. $21,494.62 10/12/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046014221
Principal investigator 1 PFIZER INC. $1,438.50 10/11/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046268187
Principal investigator 1 Bavarian Nordic A/S $63,848.00 10/10/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704511
Principal investigator 1 BioNTech SE $6,675.00 10/10/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319261
Principal investigator 1 BioNTech SE $300.00 10/06/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319321
Principal investigator 1 Novo Nordisk AS $1.40 10/06/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543611
Principal investigator 1 Novo Nordisk AS $462.60 10/05/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007127501
Principal investigator 1 Novo Nordisk AS $462.60 10/05/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007127519
Principal investigator 1 Novo Nordisk AS $462.60 10/05/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543629
Principal investigator 1 Novo Nordisk AS $462.60 10/05/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543643
Principal investigator 1 Novo Nordisk AS $462.60 10/05/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543659
Principal investigator 1 Novo Nordisk AS $462.60 10/05/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543675
Principal investigator 1 Novo Nordisk AS $462.60 10/05/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543691
Principal investigator 1 Novo Nordisk AS $462.60 10/05/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543705
Principal investigator 1 Novo Nordisk AS $1,500.00 10/04/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1008123462
Principal investigator 1 Bavarian Nordic A/S $911.00 10/03/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704449
Principal investigator 1 BioNTech SE $1,386.00 10/03/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319251
Principal investigator 1 BioNTech SE $3,798.00 10/03/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319253
Principal investigator 1 Novo Nordisk AS $23.06 10/03/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007847203
Principal investigator 1 Novo Nordisk AS $23.06 10/02/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007651229
Principal investigator 1 PFIZER INC. $917.05 10/02/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046009197
Principal investigator 1 Boehringer Ingelheim International GmbH $3,209.70 10/01/2023 Non-covered Recipient Entity
Pmg Research Of Wilmington
Phase III efficacy for obesity without T2DM No dispute reported 06/30/2026 1007645997
Principal investigator 1 Boehringer Ingelheim International GmbH $3,151.04 10/01/2023 Non-covered Recipient Entity
Pmg Research Of Wilmington
phase III efficacy for obesity with T2DM No dispute reported 06/30/2026 1007646005
Principal investigator 1 PFIZER INC. $422.00 09/28/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046240419
Principal investigator 1 Novo Nordisk AS $23.06 09/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007847197
Principal investigator 1 PFIZER INC. $6,799.32 09/27/2023 Non-covered Recipient Entity
Accellacare US Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046200473
Principal investigator 1 Novo Nordisk AS $7.27 09/25/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865809
Principal investigator 1 Novo Nordisk AS $23.06 09/25/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865821
Principal investigator 1 PFIZER INC. $4,653.89 09/23/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1045956457
Principal investigator 1 PFIZER INC. $11,167.12 09/23/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046078991
Principal investigator 1 Novo Nordisk AS $17,594.38 09/22/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007550625
Principal investigator 1 Novo Nordisk AS $437.60 09/22/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007772253
Principal investigator 1 Novo Nordisk AS $3,500.00 09/22/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 1008206969
Principal investigator 1 Novo Nordisk AS $556.94 09/22/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1008717963
Principal investigator 1 Novo Nordisk AS $3,664.21 09/22/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1009259873
Principal investigator 1 PFIZER INC. $500.00 09/22/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046053499
Principal investigator 1 Bavarian Nordic A/S $439.00 09/21/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704803
Principal investigator 1 BioNTech SE $22,942.00 09/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060313403
Principal investigator 1 PFIZER INC. $4,751.85 09/16/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1045920549
Principal investigator 1 GlaxoSmithKline, LLC. $13,030.38 09/15/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT No dispute reported 06/30/2026 1127786719
Principal investigator 1 Novo Nordisk AS $23.06 09/15/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865851
Principal investigator 1 PFIZER INC. $1,060.43 09/15/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046238665
Principal investigator 1 PFIZER INC. $12,952.67 09/15/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046258133
Principal investigator 1 PFIZER INC. $6,400.00 09/14/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046248699
Principal investigator 1 Bavarian Nordic A/S $493.00 09/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704523
Principal investigator 1 PFIZER INC. $403.92 09/11/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045931063
Principal investigator 1 PFIZER INC. $403.92 09/11/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046229901
Principal investigator 1 PFIZER INC. $106,657.65 09/09/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046243653
Principal investigator 1 Novo Nordisk AS $23.06 09/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865794
Principal investigator 1 PFIZER INC. $6,154.04 09/07/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046239031
Principal investigator 1 PFIZER INC. $3,180.47 09/07/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046247841
Principal investigator 1 Bavarian Nordic A/S $3,267.00 09/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704475
Principal investigator 1 BioNTech SE $9,300.00 09/06/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060313401
Principal investigator 1 GlaxoSmithKline, LLC. $6,762.56 09/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI-CEN No dispute reported 06/30/2026 1006143433
Principal investigator 1 Janssen Pharmaceuticals, Inc $35,084.00 09/06/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095563
Principal investigator 1 Novo Nordisk AS $23.06 09/06/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007212765
Principal investigator 1 PFIZER INC. $403.92 09/06/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1045873481
Principal investigator 1 Novo Nordisk AS $23.06 09/05/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865836
Principal investigator 1 PFIZER INC. $550.23 09/05/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046132385
Principal investigator 1 Novo Nordisk AS $29.50 09/02/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 1007631545
Principal investigator 1 PFIZER INC. $4,477.70 09/02/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046248459
Principal investigator 1 Bavarian Nordic A/S $1,953.00 09/01/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704425
Principal investigator 1 BioNTech SE $13,514.00 09/01/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060313399
Principal investigator 1 PFIZER INC. $1,600.00 09/01/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046152019
Principal investigator 1 PFIZER INC. $5,313.30 08/30/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1045989647
Recipient PFIZER INC. $780.00 08/29/2023 Covered Recipient Physician BNT162 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046266645
Principal investigator 1 Novo Nordisk AS $1,250.00 08/28/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 1008450181
Principal investigator 1 PFIZER INC. $85,840.00 08/24/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1045977929
Principal investigator 1 PFIZER INC. $16,921.56 08/24/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046225787
Principal investigator 1 PFIZER INC. $17,289.65 08/24/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046256293
Principal investigator 1 PFIZER INC. $403.92 08/24/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046259933
Principal investigator 1 Bavarian Nordic A/S $14,249.00 08/23/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704815
Principal investigator 1 BioNTech SE $8,330.00 08/23/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060318151
Principal investigator 1 Novo Nordisk AS $23.06 08/23/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007212751
Principal investigator 1 PFIZER INC. $1,238.14 08/23/2023 Non-covered Recipient Entity
Accellacare US Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046154725
Principal investigator 1 Novo Nordisk AS $9,103.85 08/21/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 1008348963
Principal investigator 1 Novo Nordisk AS $2,848.13 08/21/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1009259855
Principal investigator 1 PFIZER INC. $733.64 08/21/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045953213
Principal investigator 1 PFIZER INC. $7,428.84 08/19/2023 Non-covered Recipient Entity
Accellacare US Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046235013
Principal investigator 1 Bavarian Nordic A/S $5,425.00 08/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704565
Principal investigator 1 BioNTech SE $5,045.00 08/18/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319027
Principal investigator 1 Novo Nordisk AS $710.72 08/18/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007772247
Principal investigator 1 Novo Nordisk AS $23.06 08/18/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007849509
Principal investigator 1 Novo Nordisk AS $14,732.01 08/18/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1008123447
Principal investigator 1 Novo Nordisk AS $16,292.69 08/18/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543593
Principal investigator 1 PFIZER INC. $1,491.25 08/17/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1045925199
Principal investigator 1 PFIZER INC. $739.80 08/17/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046166587
Principal investigator 1 Janssen Pharmaceuticals, Inc $11,558.00 08/16/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095567
Principal investigator 1 Novo Nordisk AS $23.06 08/11/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865783
Principal investigator 1 PFIZER INC. $50.00 08/11/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1045965745
Principal investigator 1 PFIZER INC. $4,961.46 08/11/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046077271
Principal investigator 1 PFIZER INC. $6,691.09 08/11/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046144211
Principal investigator 1 Bavarian Nordic A/S $30,597.00 08/10/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704499
Principal investigator 1 BioNTech SE $18,892.00 08/10/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060317335
Principal investigator 1 BioNTech SE $900.00 08/10/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319013
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 08/09/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127785367
Principal investigator 1 PFIZER INC. $893.20 08/09/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046157995
Principal investigator 1 PFIZER INC. $26,691.36 08/08/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046165077
Principal investigator 1 PFIZER INC. $3,600.00 08/08/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046193537
Principal investigator 1 Novo Nordisk AS $23,194.53 08/04/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007550639
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,494.00 08/02/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095565
Principal investigator 1 PFIZER INC. $11,143.26 08/02/2023 Non-covered Recipient Entity
Accellacare US Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046053483
Principal investigator 1 Novo Nordisk AS $990.37 07/31/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1007054595
Principal investigator 1 Novo Nordisk AS $1,497.43 07/31/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007772239
Principal investigator 1 Novo Nordisk AS $5,912.50 07/31/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1008123433
Principal investigator 1 Novo Nordisk AS $6,886.81 07/31/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1009259839
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 07/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127792176
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007315437
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007315447
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007315457
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007315469
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007315479
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007315489
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007469875
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007611781
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007611787
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007611793
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007611799
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007611807
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007611815
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007611821
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007611827
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007611833
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007611839
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007772195
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007772201
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007772208
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007772215
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007807615
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007807623
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007807629
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007807635
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007807641
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008189357
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008189371
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008189385
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008189399
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008189415
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008189431
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008189445
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008189457
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008189471
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008189485
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008957579
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008957595
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008957615
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008957633
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008957651
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008957667
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008957685
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008957701
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008957717
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008972893
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008972911
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008972929
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008972945
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008972961
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008972977
Principal investigator 1 Novo Nordisk AS $11.38 07/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1008972993
Principal investigator 1 PFIZER INC. $11,820.00 07/27/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE VIROLOGICAL RESPONSE AND SAFETY OF ORAL PF07817883 IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 No dispute reported 06/30/2026 1046093652
Principal investigator 1 Bavarian Nordic A/S $31,645.00 07/26/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704841
Principal investigator 1 BioNTech SE $9,141.00 07/26/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319033
Principal investigator 1 GlaxoSmithKline, LLC. $39.00 07/26/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127785359
Principal investigator 1 GlaxoSmithKline, LLC. $100.00 07/26/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127792164
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 07/26/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127792172
Principal investigator 1 Novo Nordisk AS $6,536.28 07/26/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1008123401
Principal investigator 1 Novo Nordisk AS $1,875.00 07/26/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1008123419
Principal investigator 1 PFIZER INC. $15,500.00 07/26/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045908763
Principal investigator 1 PFIZER INC. $1,000.00 07/26/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1045962359
Principal investigator 1 PFIZER INC. $61,026.02 07/26/2023 Non-covered Recipient Entity
Accellacare US Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046077245
Principal investigator 1 PFIZER INC. $29,848.42 07/26/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046346993
Principal investigator 1 Novo Nordisk AS $23.06 07/25/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007203425
Principal investigator 1 PFIZER INC. $362.37 07/21/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046345679
Principal investigator 1 PFIZER INC. $7,000.00 07/19/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046031347
Principal investigator 1 PFIZER INC. $13,998.38 07/19/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046111819
Principal investigator 1 Bavarian Nordic A/S $22,852.00 07/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704571
Principal investigator 1 BioNTech SE $13,195.00 07/18/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060318153
Principal investigator 1 Novo Nordisk AS $23.06 07/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007203409
Principal investigator 1 PFIZER INC. $82,931.58 07/15/2023 Non-covered Recipient Entity
Accellacare US Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046106035
Principal investigator 1 GlaxoSmithKline, LLC. $15,786.54 07/14/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127785355
Principal investigator 1 Novo Nordisk AS $23.06 07/14/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007203395
Principal investigator 1 PFIZER INC. $362.37 07/14/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046144183
Principal investigator 1 PFIZER INC. $14,973.50 07/13/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045905825
Principal investigator 1 PFIZER INC. $4,850.00 07/13/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1045979923
Principal investigator 1 GlaxoSmithKline, LLC. $800.00 07/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1127786697
Principal investigator 1 PFIZER INC. $246.60 07/12/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046335931
Principal investigator 1 Bavarian Nordic A/S $101,403.00 07/11/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704517
Principal investigator 1 BioNTech SE $1,386.00 07/11/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060317337
Principal investigator 1 PFIZER INC. $17,551.34 07/11/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046061251
Principal investigator 1 PFIZER INC. $362.37 07/08/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046108275
Principal investigator 1 PFIZER INC. $49,048.74 07/07/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1045906483
Principal investigator 1 PFIZER INC. $175.50 07/06/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045906501
Principal investigator 1 PFIZER INC. $493.20 07/06/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046156003
Principal investigator 1 Novo Nordisk AS $23.06 07/05/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007203381
Principal investigator 1 Novo Nordisk AS $23.06 07/05/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007772221
Principal investigator 1 Bavarian Nordic A/S $14,339.00 07/04/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704463
Principal investigator 1 BioNTech SE $9,495.00 07/04/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060317331
Principal investigator 1 BioNTech SE $3,167.00 07/04/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060317333
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007469803
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007469813
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007469825
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007469835
Principal investigator 1 Novo Nordisk AS $19.98 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007469845
Principal investigator 1 Novo Nordisk AS $130.98 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007469857
Principal investigator 1 Novo Nordisk AS $15.98 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007469865
Principal investigator 1 Novo Nordisk AS $7.49 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007777945
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007777951
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007777957
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007811387
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007811393
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007811401
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007811407
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007811413
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007811419
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007811425
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007811431
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007811437
Principal investigator 1 Novo Nordisk AS $10.82 06/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007811443
Principal investigator 1 PFIZER INC. $1,479.60 06/29/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046335431
Principal investigator 1 Bavarian Nordic A/S $14,071.00 06/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704847
Principal investigator 1 BioNTech SE $7,259.00 06/28/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319077
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 06/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127783446
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 06/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127783448
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 06/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127785363
Principal investigator 1 GlaxoSmithKline, LLC. $1,600.00 06/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127785365
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 06/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127786713
Principal investigator 1 GlaxoSmithKline, LLC. $400.00 06/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127786717
Principal investigator 1 Novo Nordisk AS $23.06 06/28/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007651261
Principal investigator 1 PFIZER INC. $12,811.50 06/27/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045901275
Principal investigator 1 Novo Nordisk AS $23.06 06/26/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007651293
Principal investigator 1 PFIZER INC. $18,009.15 06/24/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046025982
Principal investigator 1 Novo Nordisk AS $15,910.50 06/23/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007550611
Principal investigator 1 Novo Nordisk AS $3,591.61 06/23/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007772233
Principal investigator 1 Novo Nordisk AS $30,500.15 06/23/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1008123387
Principal investigator 1 Novo Nordisk AS $1,641.12 06/23/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1008717947
Principal investigator 1 Novo Nordisk AS $3,664.04 06/23/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1009259823
Principal investigator 1 PFIZER INC. $6,904.80 06/22/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046312531
Principal investigator 1 PFIZER INC. $84,938.80 06/21/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1045903679
Principal investigator 1 PFIZER INC. $400.73 06/21/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046324266
Principal investigator 1 Bavarian Nordic A/S $14,874.00 06/20/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704791
Principal investigator 1 BioNTech SE $8,413.00 06/20/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319057
Principal investigator 1 Novavax Inc $248,502.00 06/16/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055263549
Principal investigator 1 Novo Nordisk AS $23.06 06/16/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007651281
Principal investigator 1 PFIZER INC. $10,357.20 06/16/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046068673
Principal investigator 1 GlaxoSmithKline, LLC. $7,021.08 06/14/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127786705
Principal investigator 1 PFIZER INC. $18,741.60 06/14/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045972171
Principal investigator 1 Bavarian Nordic A/S $18,109.00 06/13/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704535
Principal investigator 1 BioNTech SE $4,075.00 06/13/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319071
Principal investigator 1 PFIZER INC. $11,050.00 06/13/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1045908777
Recipient PFIZER INC. $3,200.00 06/13/2023 Covered Recipient Physician BNT162 CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046237081
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,310.00 06/09/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095535
Principal investigator 1 Novo Nordisk AS $2.80 06/09/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1006638977
Principal investigator 1 Bavarian Nordic A/S $21,739.00 06/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704481
Principal investigator 1 BioNTech SE $23,687.00 06/08/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319065
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,500.00 06/08/2023 Non-covered Recipient Entity
Pmg Research
Ph IIb dose finding vs placebo in patients with Ob No dispute reported 06/30/2026 1022137059
Principal investigator 1 PFIZER INC. $5,265.00 06/08/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045907519
Principal investigator 1 PFIZER INC. $3,285.95 06/08/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046043399
Principal investigator 1 GlaxoSmithKline, LLC. $400.00 06/07/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127785357
Principal investigator 1 PFIZER INC. $733.64 06/07/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046202095
Principal investigator 1 Novo Nordisk AS $23.06 06/06/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007651273
Principal investigator 1 PFIZER INC. $13,000.00 06/06/2023 Non-covered Recipient Entity
Accellacare US Inc
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046001577
Principal investigator 1 PFIZER INC. $400.00 06/03/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046335487
Principal investigator 1 Janssen Pharmaceuticals, Inc $18,196.00 06/02/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095533
Principal investigator 1 Bavarian Nordic A/S $18,370.00 05/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704859
Principal investigator 1 BioNTech SE $6,431.00 05/30/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319079
Principal investigator 1 PFIZER INC. $32.90 05/30/2023 Non-covered Recipient Entity
Accellacare Wilmington
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045940571
Principal investigator 1 PFIZER INC. $1,912.80 05/30/2023 Non-covered Recipient Entity
Accellacare Wilmington
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045977909
Principal investigator 1 PFIZER INC. $1,398.09 05/27/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046299839
Principal investigator 1 Novo Nordisk AS $199.00 05/26/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1006638871
Principal investigator 1 Novo Nordisk AS $199.00 05/26/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1006638889
Principal investigator 1 Novo Nordisk AS $199.00 05/26/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1006638917
Principal investigator 1 Novo Nordisk AS $199.00 05/26/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1006638939
Principal investigator 1 Novo Nordisk AS $199.00 05/26/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1006638957
Principal investigator 1 Novo Nordisk AS $1,980.75 05/26/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1007054579
Principal investigator 1 Novo Nordisk AS $35,509.99 05/26/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1007306137
Principal investigator 1 Novo Nordisk AS $35,571.70 05/26/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007550597
Principal investigator 1 PFIZER INC. $7,371.00 05/26/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045902467
Principal investigator 1 PFIZER INC. $1,202.19 05/25/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1045988615
Principal investigator 1 PFIZER INC. $2,877.00 05/25/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046027737
Principal investigator 1 PFIZER INC. $54,991.80 05/25/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046145447
Principal investigator 1 Bavarian Nordic A/S $16,410.00 05/24/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704821
Principal investigator 1 BioNTech SE $38,420.00 05/24/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 05/24/2023 Non-covered Recipient Entity
PMG RESEARCH
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 977110977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $104,829.78 05/22/2023 Non-covered Recipient Entity
PMG RESEARCH
A PHASE 2 STUDY TO ASSESS THE VIROLOGIC EFFICACY OF REGN10933+REGN10987 ACROSS DIFFERENT DOSE REGIMENS IN OUTPATIENTS WITH SARS-COV-2 INFECTION No dispute reported 06/30/2026 977110555
Principal investigator 1 Bavarian Nordic A/S $8,563.00 05/19/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704579
Principal investigator 1 Novo Nordisk AS $23.06 05/19/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007651249
Principal investigator 1 PFIZER INC. $1,777.58 05/19/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046052837
Principal investigator 1 ModernaTX, Inc. $750.00 05/17/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299901
Principal investigator 1 Bavarian Nordic A/S $15,233.00 05/16/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704553
Principal investigator 1 BioNTech SE $3,368.00 05/16/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319073
Principal investigator 1 PFIZER INC. $14,796.00 05/16/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046186659
Principal investigator 1 PFIZER INC. $6,784.00 05/16/2023 Non-covered Recipient Entity
Accellacare Wilmington
A STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFECTIOUS RESPIRATORY ILLNESSES INCLUDING COVID19 AND RSV IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046251629
Principal investigator 1 Novo Nordisk AS $8,700.00 05/12/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1007306127
Principal investigator 1 Novo Nordisk AS $23.06 05/12/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007651239
Principal investigator 1 Novo Nordisk AS $20.10 05/12/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1008123373
Principal investigator 1 PFIZER INC. $3,376.37 05/12/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046024941
Principal investigator 1 Bavarian Nordic A/S $530.00 05/11/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988705179
Principal investigator 1 PFIZER INC. $10,850.40 05/10/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046359889
Principal investigator 1 Bavarian Nordic A/S $23,772.00 05/09/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704493
Principal investigator 1 Bavarian Nordic A/S $26,388.00 05/09/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704865
Principal investigator 1 BioNTech SE $30,311.00 05/09/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319067
Principal investigator 1 PFIZER INC. $9,617.40 05/09/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046362123
Principal investigator 1 PFIZER INC. $733.64 05/08/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046003635
Principal investigator 1 PFIZER INC. $24,542.68 05/06/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045920153
Principal investigator 1 PFIZER INC. $3,305.84 05/06/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046314177
Principal investigator 1 GlaxoSmithKline, LLC. $22,644.37 05/05/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI-CEN No dispute reported 06/30/2026 1006143453
Principal investigator 1 PFIZER INC. $4,081.23 05/04/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046360601
Principal investigator 1 Bavarian Nordic A/S $12,475.00 05/03/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704443
Principal investigator 1 BioNTech SE $31,797.00 05/03/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319059
Principal investigator 1 BioNTech SE $5,697.00 05/03/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319061
Principal investigator 1 GlaxoSmithKline, LLC. $4,178.38 05/03/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI-CEN No dispute reported 06/30/2026 1006143079
Principal investigator 1 Janssen Pharmaceuticals, Inc $9,410.00 05/03/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095531
Principal investigator 1 Novavax Inc $22,198.00 05/03/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055263545
Principal investigator 1 PFIZER INC. $366.82 05/02/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046277773
Principal investigator 1 PFIZER INC. $857.62 04/29/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045919853
Principal investigator 1 PFIZER INC. $2,378.64 04/28/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 MASTER PROTOCOL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS AT HIGH RISK OF SEVERE RSV DISEASE No dispute reported 06/30/2026 1045864319
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299591
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299593
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299595
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299597
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299599
Principal investigator 1 ModernaTX, Inc. $537.37 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299601
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299603
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299605
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299607
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299609
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299611
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299613
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299615
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299617
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299619
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299621
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299623
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299625
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299627
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299629
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299631
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299633
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299635
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299637
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299639
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299641
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299643
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299645
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299647
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299649
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299651
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299653
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299655
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299657
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299659
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299661
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299663
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299665
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299667
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299669
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299671
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299673
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299675
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299677
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299679
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299681
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299683
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299685
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299687
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299689
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299691
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299693
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299695
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299697
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299699
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299701
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299703
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299705
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299707
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299709
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299711
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299713
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299715
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299717
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299719
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299721
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299723
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299725
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299727
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299729
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299731
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299733
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299735
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299737
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299739
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299741
Principal investigator 1 ModernaTX, Inc. $537.37 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299743
Principal investigator 1 ModernaTX, Inc. $537.37 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299745
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299747
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299749
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299751
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299753
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299755
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299757
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299759
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299761
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299763
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299765
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299767
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299769
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299771
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299773
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299775
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299777
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299779
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299781
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299783
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299785
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299787
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299789
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299791
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299793
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299795
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299797
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299799
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299801
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299803
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299805
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299807
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299809
Principal investigator 1 ModernaTX, Inc. $537.37 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299811
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299813
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299815
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299817
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299819
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299821
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299823
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299825
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299827
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299829
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299831
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299833
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299835
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299837
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299839
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299841
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299843
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299845
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299847
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299849
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299851
Principal investigator 1 ModernaTX, Inc. $537.37 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299853
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299855
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299857
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299859
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299861
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299863
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299865
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299867
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299869
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299871
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299873
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299875
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299877
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299879
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299881
Principal investigator 1 ModernaTX, Inc. $409.12 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299883
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299885
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299887
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299889
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299891
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299893
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299895
Principal investigator 1 ModernaTX, Inc. $473.24 04/27/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299897
Principal investigator 1 PFIZER INC. $8,898.15 04/27/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045977895
Principal investigator 1 PFIZER INC. $724.74 04/27/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046181771
Principal investigator 1 Bavarian Nordic A/S $19,803.00 04/26/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704835
Principal investigator 1 Novavax Inc $2,018.00 04/26/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265555
Principal investigator 1 Novo Nordisk AS $17,533.29 04/26/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007550583
Principal investigator 1 Novo Nordisk AS $23.06 04/25/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007203367
Principal investigator 1 Novo Nordisk AS $833.04 04/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1008717929
Principal investigator 1 GlaxoSmithKline, LLC. $82,664.01 04/21/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127786709
Principal investigator 1 GlaxoSmithKline, LLC. $82,664.01 04/21/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127790932
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,750.00 04/21/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095529
Principal investigator 1 PFIZER INC. $1,715.24 04/21/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046093637
Principal investigator 1 PFIZER INC. $5,425.20 04/21/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046289426
Principal investigator 1 Novo Nordisk AS $0.98 04/19/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1006638847
Principal investigator 1 Bavarian Nordic A/S $35,800.00 04/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704559
Principal investigator 1 BioNTech SE $6,217.00 04/18/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060317403
Principal investigator 1 Novo Nordisk AS $23.06 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1006677947
Principal investigator 1 Novo Nordisk AS $97.65 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1006677961
Principal investigator 1 Novo Nordisk AS $112.28 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1006677984
Principal investigator 1 Novo Nordisk AS $197.40 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007203309
Principal investigator 1 Novo Nordisk AS $197.40 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007203325
Principal investigator 1 Novo Nordisk AS $208.95 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007203339
Principal investigator 1 Novo Nordisk AS $210.00 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007203353
Principal investigator 1 Novo Nordisk AS $171.15 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008007773
Principal investigator 1 Novo Nordisk AS $197.40 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008007783
Principal investigator 1 Novo Nordisk AS $197.40 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008007795
Principal investigator 1 Novo Nordisk AS $197.40 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008007805
Principal investigator 1 Novo Nordisk AS $197.40 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008007815
Principal investigator 1 Novo Nordisk AS $197.40 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008007827
Principal investigator 1 Novo Nordisk AS $197.40 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008007837
Principal investigator 1 Novo Nordisk AS $197.40 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008007847
Principal investigator 1 Novo Nordisk AS $197.40 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008007857
Principal investigator 1 Novo Nordisk AS $197.40 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008007867
Principal investigator 1 Novo Nordisk AS $4.50 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865679
Principal investigator 1 Novo Nordisk AS $63.00 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865695
Principal investigator 1 Novo Nordisk AS $64.05 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865711
Principal investigator 1 Novo Nordisk AS $81.90 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865729
Principal investigator 1 Novo Nordisk AS $82.95 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865747
Principal investigator 1 Novo Nordisk AS $156.24 04/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865765
Principal investigator 1 PFIZER INC. $1,645.37 04/15/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046094039
Principal investigator 1 Novo Nordisk AS $23.06 04/14/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865661
Principal investigator 1 Bavarian Nordic A/S $19,649.00 04/13/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704529
Principal investigator 1 BioNTech SE $15,517.00 04/13/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319069
Principal investigator 1 Novo Nordisk AS $23.06 04/13/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1007306105
Principal investigator 1 PFIZER INC. $15,011.70 04/12/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046030011
Principal investigator 1 GlaxoSmithKline, LLC. $32,846.22 04/07/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1127792168
Principal investigator 1 PFIZER INC. $2,500.00 04/07/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1046142481
Principal investigator 1 Novavax Inc $348.00 04/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265557
Principal investigator 1 GlaxoSmithKline, LLC. $1,700.00 04/05/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1006143029
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 04/05/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI-CEN No dispute reported 06/30/2026 1006143059
Principal investigator 1 PFIZER INC. $2,923.58 04/05/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1045919871
Principal investigator 1 PFIZER INC. $77,304.23 04/05/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045998695
Principal investigator 1 Bavarian Nordic A/S $44,400.00 04/04/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704457
Principal investigator 1 BioNTech SE $30,544.00 04/04/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319063
Principal investigator 1 Novavax Inc $11,061.00 04/04/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055263547
Principal investigator 1 Novo Nordisk AS $23.06 04/04/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1006677923
Principal investigator 1 PFIZER INC. $19,306.68 04/04/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046000011
Principal investigator 1 PFIZER INC. $7,000.00 03/31/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046074317
Principal investigator 1 PFIZER INC. $11,740.90 03/30/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046148805
Principal investigator 1 Bavarian Nordic A/S $13,467.00 03/29/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704853
Principal investigator 1 Novo Nordisk AS $23.06 03/29/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007849489
Principal investigator 1 PFIZER INC. $421.30 03/29/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1045971575
Principal investigator 1 Janssen Pharmaceuticals, Inc $8,000.00 03/28/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095503
Principal investigator 1 Novo Nordisk AS $23.06 03/27/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007849483
Principal investigator 1 Novo Nordisk AS $1,360.29 03/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1007054563
Principal investigator 1 Novo Nordisk AS $29,081.78 03/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007756467
Principal investigator 1 Novo Nordisk AS $400.00 03/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007756473
Principal investigator 1 Novo Nordisk AS $1,148.32 03/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007777927
Principal investigator 1 Novo Nordisk AS $9,281.30 03/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1008123343
Principal investigator 1 Novo Nordisk AS $600.00 03/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1008123359
Principal investigator 1 Novo Nordisk AS $2,136.54 03/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1009295187
Principal investigator 1 Novo Nordisk AS $300.00 03/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1009295203
Principal investigator 1 PFIZER INC. $216.00 03/23/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045908319
Principal investigator 1 Janssen Pharmaceuticals, Inc $152,234.00 03/22/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095505
Principal investigator 1 PFIZER INC. $11,149.06 03/22/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046153865
Principal investigator 1 PFIZER INC. $500.00 03/22/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046282367
Principal investigator 1 Bavarian Nordic A/S $30,441.00 03/21/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704797
Principal investigator 1 BioNTech SE $1,199.00 03/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319051
Principal investigator 1 BioNTech SE $3,306.00 03/21/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319053
Principal investigator 1 Novo Nordisk AS $23.06 03/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007849495
Principal investigator 1 Novo Nordisk AS $23.06 03/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007849503
Principal investigator 1 Bavarian Nordic A/S $77,983.00 03/15/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704541
Principal investigator 1 BioNTech SE $30,179.00 03/15/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319043
Principal investigator 1 Novavax Inc $21,382.00 03/15/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055261591
Principal investigator 1 PFIZER INC. $161,126.55 03/15/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046018879
Principal investigator 1 PFIZER INC. $23,281.78 03/15/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046026183
Principal investigator 1 PFIZER INC. $16,700.30 03/15/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046186889
Principal investigator 1 PFIZER INC. $2,482.98 03/11/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046295461
Principal investigator 1 PFIZER INC. $11,149.06 03/11/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046296981
Principal investigator 1 PFIZER INC. $1,800.90 03/10/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046143733
Principal investigator 1 PFIZER INC. $1,246.70 03/09/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045921085
Principal investigator 1 PFIZER INC. $11,727.45 03/09/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046069094
Principal investigator 1 Novavax Inc $8,893.00 03/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055263543
Principal investigator 1 Novo Nordisk AS $23.06 03/08/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007772227
Principal investigator 1 Novo Nordisk AS $23.06 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007203439
Principal investigator 1 Novo Nordisk AS $23.06 03/07/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1007306116
Principal investigator 1 Novo Nordisk AS $299.80 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007550557
Principal investigator 1 Novo Nordisk AS $299.80 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007550569
Principal investigator 1 Novo Nordisk AS $299.80 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543429
Principal investigator 1 Novo Nordisk AS $299.80 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543445
Principal investigator 1 Novo Nordisk AS $299.80 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543461
Principal investigator 1 Novo Nordisk AS $299.80 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543477
Principal investigator 1 Novo Nordisk AS $299.80 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543493
Principal investigator 1 Novo Nordisk AS $299.80 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543509
Principal investigator 1 Novo Nordisk AS $299.80 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543525
Principal investigator 1 Novo Nordisk AS $299.80 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543543
Principal investigator 1 Novo Nordisk AS $299.80 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543559
Principal investigator 1 Novo Nordisk AS $299.80 03/07/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1008543577
Principal investigator 1 PFIZER INC. $180,729.02 03/07/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046294341
Principal investigator 1 PFIZER INC. $24,927.00 03/04/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 1 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1045989029
Principal investigator 1 PFIZER INC. $4,899.12 03/01/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046291739
Principal investigator 1 BioNTech SE $27,353.00 02/28/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319047
Principal investigator 1 Novavax Inc $8,284.00 02/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055259645
Principal investigator 1 Novo Nordisk AS $23.06 02/28/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007777933
Principal investigator 1 Novo Nordisk AS $70.00 02/28/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 1008348949
Principal investigator 1 PFIZER INC. $73,240.20 02/28/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046215409
Principal investigator 1 PFIZER INC. $300.00 02/25/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 1045921371
Principal investigator 1 PFIZER INC. $21,366.45 02/25/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046068073
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 02/24/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI-CEN No dispute reported 06/30/2026 1006143049
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 02/24/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI-CEN No dispute reported 06/30/2026 1006143465
Principal investigator 1 Novo Nordisk AS $300.00 02/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1006677891
Principal investigator 1 Novo Nordisk AS $119,371.39 02/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007756461
Principal investigator 1 Novo Nordisk AS $1,054.50 02/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1008717913
Principal investigator 1 Novo Nordisk AS $1,720.99 02/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1009295169
Principal investigator 1 PFIZER INC. $5,088.00 02/24/2023 Non-covered Recipient Entity
Accellacare
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045865869
Principal investigator 1 PFIZER INC. $38,403.45 02/24/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045908305
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $42,409.37 02/24/2023 Non-covered Recipient Entity
PMG RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 No dispute reported 06/30/2026 977093655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $38,500.55 02/24/2023 Non-covered Recipient Entity
PMG RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 No dispute reported 06/30/2026 977093661
Principal investigator 1 Janssen Pharmaceuticals, Inc $172,772.00 02/23/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095507
Principal investigator 1 PFIZER INC. $16,065.00 02/23/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1045899837
Principal investigator 1 PFIZER INC. $13,686.30 02/23/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046044707
Principal investigator 1 Bavarian Nordic A/S $22,548.00 02/22/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704809
Principal investigator 1 BioNTech SE $62,883.00 02/22/2023 Non-covered Recipient Entity
PMG Research Inc
Pre-commercial No dispute reported 06/30/2026 1060319045
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 02/22/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1006143015
Principal investigator 1 GlaxoSmithKline, LLC. $7,500.00 02/22/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1006143039
Principal investigator 1 Novavax Inc $40,604.00 02/22/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055264547
Principal investigator 1 Novo Nordisk AS $23.06 02/22/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007777939
Principal investigator 1 Novo Nordisk AS $13,235.69 02/22/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1008123329
Principal investigator 1 PFIZER INC. $94,277.55 02/18/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046163737
Principal investigator 1 GlaxoSmithKline, LLC. $8,525.88 02/17/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1006143069
Principal investigator 1 GlaxoSmithKline, LLC. $3,008.61 02/17/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1006143423
Principal investigator 1 GlaxoSmithKline, LLC. $37,112.13 02/17/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1006143443
Principal investigator 1 Novo Nordisk AS $23.06 02/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1007651219
Principal investigator 1 Novo Nordisk AS $7,000.00 02/17/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 1007756455
Principal investigator 1 Bavarian Nordic A/S $19,406.00 02/16/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704547
Principal investigator 1 Novavax Inc $38,204.00 02/16/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055259647
Principal investigator 1 Novo Nordisk AS $6.23 02/16/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1007306083
Principal investigator 1 Novo Nordisk AS $23.06 02/16/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1007306095
Principal investigator 1 PFIZER INC. $12,960.00 02/15/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045902481
Principal investigator 1 PFIZER INC. $12,006.68 02/15/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045972157
Principal investigator 1 PFIZER INC. $38,684.25 02/15/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046181789
Principal investigator 1 PFIZER INC. $733.64 02/13/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046007965
Principal investigator 1 PFIZER INC. $2,164.60 02/11/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046091967
Principal investigator 1 PFIZER INC. $3,392.00 02/10/2023 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046069079
Principal investigator 1 PFIZER INC. $33,364.67 02/10/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046297085
Principal investigator 1 Bavarian Nordic A/S $25,796.00 02/09/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704487
Principal investigator 1 Novavax Inc $61,904.00 02/09/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055261589
Principal investigator 1 PFIZER INC. $229,088.66 02/07/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046062527
Principal investigator 1 PFIZER INC. $678.40 02/03/2023 Non-covered Recipient Entity
Accellacare Wilmington
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1045906247
Principal investigator 1 PFIZER INC. $14,476.79 02/03/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 1046075721
Principal investigator 1 PFIZER INC. $1,767.15 02/03/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046128953
Principal investigator 1 Bavarian Nordic A/S $48,654.00 02/02/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704431
Principal investigator 1 PFIZER INC. $2,572.86 02/01/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046186869
Principal investigator 1 Novo Nordisk AS $70.00 01/31/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 1008450167
Principal investigator 1 Novo Nordisk AS $39.96 01/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007777907
Principal investigator 1 Novo Nordisk AS $39.96 01/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007777913
Principal investigator 1 Novo Nordisk AS $0.69 01/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1007841665
Principal investigator 1 Novo Nordisk AS $0.69 01/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1007841671
Principal investigator 1 Novo Nordisk AS $0.69 01/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1008717857
Principal investigator 1 Novo Nordisk AS $0.69 01/30/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1008717875
Principal investigator 1 Bavarian Nordic A/S $87,552.00 01/25/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704829
Principal investigator 1 Janssen Pharmaceuticals, Inc $64,440.00 01/25/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095509
Principal investigator 1 Novo Nordisk AS $10,615.69 01/25/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1007566548
Principal investigator 1 Novo Nordisk AS $748.71 01/25/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007777920
Principal investigator 1 Novo Nordisk AS $833.04 01/25/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1008717897
Principal investigator 1 Novo Nordisk AS $2,669.77 01/25/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1008865645
Principal investigator 1 PFIZER INC. $28,128.60 01/25/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1045887763
Principal investigator 1 Novo Nordisk AS $23.06 01/24/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1009295137
Principal investigator 1 PFIZER INC. $9,858.00 01/24/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046354565
Principal investigator 1 Novo Nordisk AS $11.64 01/23/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 1007566535
Principal investigator 1 Bavarian Nordic A/S $51,544.00 01/20/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704585
Principal investigator 1 Novo Nordisk AS $12.30 01/20/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1007841651
Principal investigator 1 Novo Nordisk AS $12.30 01/20/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 1007841657
Principal investigator 1 PFIZER INC. $2,731.05 01/19/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 1046027273
Principal investigator 1 PFIZER INC. $14,623.38 01/18/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046145429
Principal investigator 1 PFIZER INC. $857.62 01/18/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1046349623
Principal investigator 1 Novo Nordisk AS $23.06 01/16/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1009295119
Principal investigator 1 PFIZER INC. $9,433.82 01/14/2023 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1045939249
Principal investigator 1 Novo Nordisk AS $23.06 01/13/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1009295103
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299381
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299383
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299385
Principal investigator 1 ModernaTX, Inc. $815.67 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299387
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299389
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299391
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299393
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299395
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299397
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299399
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299401
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299403
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299405
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299407
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299409
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299411
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299413
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299415
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299417
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299419
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299421
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299423
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299425
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299427
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299429
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299431
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299433
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299435
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299437
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299439
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299441
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299443
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299445
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299447
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299449
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299451
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299453
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299459
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299461
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299463
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299465
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299467
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299469
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299471
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299473
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299475
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299477
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299479
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299481
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299483
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299485
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299487
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299489
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299491
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299493
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299495
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299497
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299499
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299501
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299503
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299505
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299507
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299509
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299511
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299513
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299515
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299517
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299519
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299521
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299523
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299525
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299527
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299529
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299531
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299533
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299535
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299537
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299539
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299541
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299543
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299545
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299547
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299549
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299551
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299553
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299555
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299557
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299559
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299561
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299563
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299565
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299567
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299569
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299571
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299573
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299575
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299577
Principal investigator 1 ModernaTX, Inc. $815.67 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299579
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299581
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299583
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299585
Principal investigator 1 ModernaTX, Inc. $409.12 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299587
Principal investigator 1 ModernaTX, Inc. $537.37 01/12/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299589
Principal investigator 1 PFIZER INC. $739.80 01/12/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045931681
Principal investigator 1 Janssen Pharmaceuticals, Inc $26,005.00 01/11/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095487
Principal investigator 1 PFIZER INC. $6,107.46 01/11/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046053877
Principal investigator 1 Bavarian Nordic A/S $68,074.00 01/10/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704505
Principal investigator 1 Novavax Inc $18,199.00 01/10/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260623
Principal investigator 1 Novo Nordisk AS $23.06 01/10/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1008267761
Principal investigator 1 Novo Nordisk AS $6.23 01/10/2023 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 1008267775
Principal investigator 1 Bavarian Nordic A/S $49,831.00 01/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988704469
Principal investigator 1 Janssen Pharmaceuticals, Inc $59,698.00 01/06/2023 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986095483
Principal investigator 1 Novavax Inc $7,836.00 01/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265553
Principal investigator 1 PFIZER INC. $1,021.95 01/05/2023 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 1046351359
Principal investigator 1 Novo Nordisk AS $23.06 01/04/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 1007777901
Principal investigator 1 Novo Nordisk AS $23.06 01/04/2023 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 1009295153
Principal investigator 1 ModernaTX, Inc. $2,000.00 01/02/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299455
Principal investigator 1 ModernaTX, Inc. $8,000.00 01/02/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042299457